NIFTY 50 Market News

Sun Pharma Share Price Live Updates: Sun Pharma's Recent Price Action

Sun Pharma Share Price Live Updates: Sun Pharma Sees Significant Daily Change

Sun Pharma Share Price Live Updates: Sun Pharma crosses below its 20-day Exponential Moving Average

Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma — Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.

Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform — Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.

Sun Pharma Share Price Live Updates: Sun Pharma's stock price falls below the 20-day SMA threshold

Stock Picks Today: Delhivery, NSE, Muthoot Finance, Sun Pharma, BEL, And More On Brokerages' Radar — Check out the top stock calls, initiations, upgrades, downgrades, and target price revisions from leading brokerages ahead of today's trade.

Sun Pharma’s specialty portfolio, Organon deal to drive growth — Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to rise in the second half of FY27 as development accelerates.

Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target price — Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.

Sun Pharma Q2 profit takes a hit on exceptional items — Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue can be attributed largely to strong sales growth in India and emerging markets, particularly in domestic formulations. Conversely, US formulation sales faced a significant downturn. The company also marked progress in its integration planning for the acquisition of Organon, following the successful completion of regulatory approvals.

Sun Pharma Q2 profit falls 36% as litigation costs hit earnings — Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.

Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional charges — Sun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported by strong growth in its domestic formulations business and emerging markets.

Stock Market Today: Sensex Rises, Nifty 50 Near 23,000; Trent Zooms 6%, Sun Pharma 2%; RIL, Jio Platforms Q2 Results Eyed — Indian stock market benchmarks, Sensex and Nifty 50, opened higher on Friday, October 30, despite rising crude oil prices, escalating US-Iran tensions and weak global market cues.

Sun Pharma Share Price Live Updates: Sun Pharma Surpasses Key Moving Average

Stocks To Watch Today: Dixon Tech, Syrma SGS, Sun Pharma, Wipro, Trent Among Others — Investors will track a range of corporate developments, including leadership changes, capacity expansion plans, new orders, project commissioning, regulatory updates and strategic investments.